This study examines the safety of a drug called fruquintinib for minority groups with advanced colorectal cancer. Fruquintinib has been linked to high blood pressure (hypertension) in some patients. Researchers want to see if this is more common in Black/African American and Hispanic/Latino populations. Participants will take fruquintinib in 4-week cycles until the cancer worsens, they can't tolerate it, or choose to stop. After treatment, follow-ups are every 3 months.

• Duration: Treatment continues until the condition worsens or participants stop, with follow-ups every 3 months.
• Participation: Open to adults over 18, specifically targeting Black/African American or Hispanic/Latino groups.
• Risks/Benefits: Potential risk of hypertension; benefits include contributing to better understanding of drug safety in minority groups.

Eligible participants must have colorectal cancer that has spread and been previously treated. They should self-identify as a minority and be in good physical health, among other criteria. Exclusions include certain health conditions like uncontrolled hypertension and recent severe health events.